Squamous Cell Cancer Clinical Trials

22 recruitingLast updated: June 18, 2026

There are 22 actively recruiting squamous cell cancer clinical trials across 11 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Squamous Cell Cancer Trials at a Glance

22 actively recruiting trials for squamous cell cancer are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 10 trials, with the heaviest enrollment activity in Houston, Nashville, and Los Angeles. Lead sponsors running squamous cell cancer studies include Dana-Farber Cancer Institute, EpiBiologics, and A2 Biotherapeutics Inc..

Browse squamous cell cancer trials by phase

Treatments under study

About Squamous Cell Cancer Clinical Trials

Looking for clinical trials for Squamous Cell Cancer? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Cell Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Cell Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Esophageal Squamous Cell CarcinomaCutaneous Squamous Cell CancerBladder Cancer+8 more
EvolveImmune United, Inc160 enrolled10 locationsNCT07217171
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Phase 2

Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:Chase

Anal Squamous Cell Cancer
Fudan University241 enrolled1 locationNCT07555678
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Not Applicable

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Pancreatic CancerSarcomaMelanoma+12 more
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT05837767
Recruiting
Phase 3

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University386 enrolled7 locationsNCT07125755
Recruiting
Not Applicable

Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer

Squamous Cell Cancer of Head and Neck (SCCHN)
University Health Network, Toronto50 enrolled1 locationNCT07348887
Recruiting
Not Applicable

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

Squamous Cell Cancer of Head and Neck (SCCHN)Head & Neck CancerCancer Pain
University of Virginia20 enrolled6 locationsNCT07405645
Recruiting
Phase 1

A Study of MGC026 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerGastric Cancer+19 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 1

SLV-154 Treatment of Metastatic Solid Tumors

Breast Cancer MetastaticOvarian CancerEndometrial Cancer+7 more
Solve Therapeutics70 enrolled9 locationsNCT06771219
Recruiting
Phase 1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Head and Neck CancerSolid TumorsHNSCC+10 more
VLP Therapeutics41 enrolled1 locationNCT06736379
Recruiting
Phase 1

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Early Phase 1

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Cutaneous Squamous Cell CancerSkin CancerCutaneous Squamous Cell Carcinoma (CSCC)
Dana-Farber Cancer Institute25 enrolled2 locationsNCT06664151
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 1

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

MelanomaSolid TumorSolid Tumor, Adult+3 more
Rise Therapeutics LLC33 enrolled1 locationNCT06398418
Recruiting
Not Applicable

Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Cancer
Ruijin Hospital212 enrolled1 locationNCT06596954
Recruiting
Phase 2

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Colorectal, CancerPancreatic CancerGastric Cancer+7 more
Udai Kammula240 enrolled1 locationNCT03935893
Recruiting
Phase 2

Towards Cure Via Only Ultra-short ICB in CSCC

Cutaneous Squamous Cell CancerCutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma (CSCC)+1 more
The Netherlands Cancer Institute41 enrolled5 locationsNCT06823479
Recruiting
Phase 2

A phase 2 study of neoadjuvant Pembrolizumab in cutaneous squamous cell carcinoma (cSCC).

Head and Neck CancerCancerCutaneous Squamous Cell Cancer
Metro South Hospital and Health Services47 enrolled3 locationsACTRN12621000901808